These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37465297)

  • 1. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):891-892. PubMed ID: 37465297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1043-1044. PubMed ID: 37583831
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
    Kadir MFA; Othman S; Nellore K
    Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biaryl Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2022 Feb; 13(2):158-159. PubMed ID: 35178168
    [No Abstract]   [Full Text] [Related]  

  • 6. Heterocyclic Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Nov; 12(11):1641-1642. PubMed ID: 34795852
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of second generation benzylidene chromanone analogues as novel, potent DHODH inhibitors in acute myeloid leukemia cells.
    Abohassan M; Al Shahrani M; Rajagopalan P
    J Biomol Struct Dyn; 2023; 41(13):6168-6177. PubMed ID: 35869648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Feb; 12(2):170-171. PubMed ID: 33603957
    [No Abstract]   [Full Text] [Related]  

  • 9. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
    Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
    Front Oncol; 2022; 12():832816. PubMed ID: 35223511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
    So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
    EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indazole and Benzoisoxazole Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2022 May; 13(5):763-764. PubMed ID: 35586439
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Poli G; Alberti M; Passoni A; Gaidano V; Pippione AC; Vitale N; Bonanni D; Rolando B; Cignetti A; Ramondetti C; Lanno A; Ferraris DM; Canepa B; Buccinnà B; Piccinini M; Rizzi M; Saglio G; Al-Karadaghi S; Boschi D; Miggiano R; Tuccinardi T; Lolli ML
    J Med Chem; 2022 Oct; 65(19):12701-12724. PubMed ID: 36162075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
    Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
    Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.
    Kamli H; Zaman GS; Shaikh A; Mobarki AA; Rajagopalan P
    Oncol Res; 2022 Jan; 28(9):899-911. PubMed ID: 34353411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.
    Houshmand M; Vitale N; Orso F; Cignetti A; Molineris I; Gaidano V; Sainas S; Giorgis M; Boschi D; Fava C; Passoni A; Gai M; Geuna M; Sora F; Iurlo A; Abruzzese E; Breccia M; Mulas O; Caocci G; Castagnetti F; Taverna D; Oliviero S; Pane F; Lolli ML; Circosta P; Saglio G
    Cell Death Dis; 2022 Jun; 13(6):576. PubMed ID: 35773274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
    Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
    Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2024 Jul; 113(1):99-109. PubMed ID: 38558052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
    Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.